4-methyl-N-[(2E)-pyrazine-2(1H)-ylidene]benzenesulfonamide | 712301-24-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-N-[(2E)-pyrazine-2(1H)-ylidene]benzenesulfonamide
• 英文别名: 4-methyl-N-(pyrazin-2-yl)benzenesulfonamide；4-methyl-N-pyrazin-2-ylbenzenesulfonamide
• CAS: 712301-24-1
• 化学式: C₁₁H₁₁N₃O₂S
• 分子量: 249.293
• InChiKey: FCASBJWPDLKUDT-UHFFFAOYSA-N

物化性质

• 沸点：
  423.8±55.0 °C(Predicted)
• 密度：
  1.375±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  80.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-碘乙酰胺 、 4-methyl-N-[(2E)-pyrazine-2(1H)-ylidene]benzenesulfonamide 以 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 以64%的产率得到N-Pyrazylglycinamid
  参考文献：
  名称：

  Scaffold hopping approach to a new series of smoothened antagonists

  摘要：

  The hedgehog (Hh) signaling pathway is a key regulator during embryonic development, while in adults, it has limited functions such as stem cell maintenance and tissue repair. The aberrant activity of the Hh signaling in adults has been linked to numerous human cancers. Inhibition of Hh signaling therefore represents a promising approach toward novel anticancer therapies. The Smoothened (Smo) receptor mediates Hh signaling. Here we report a new series of Smo antagonists which were obtained by a scaffold hopping strategy. Compounds from this new scaffold demonstrated decent inhibition of Hh pathway signaling. The new scaffold can serve as a starting point for further optimization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.079
• 作为产物：
  描述：

  2-氯吡嗪 、 对甲苯磺酰胺 在 potassium phosphate 、 [(π-allyl)Pd(tBuBrettPhos)]OTf 作用下， 以 仲丁醇 为溶剂， 反应 3.0h， 以61%的产率得到4-methyl-N-[(2E)-pyrazine-2(1H)-ylidene]benzenesulfonamide
  参考文献：
  名称：

  通过具有联芳基/联吡唑烷基膦的中性或阳离子π-烯丙基钯配合物生成活性“ L-Pd（0）”：具有挑战性的交叉偶联反应的合成，机理和结构-活性研究

  摘要：

  已经开发出两类新的高活性但空气和水分稳定的π-R-烯丙基钯铝配合物，它们含有庞大的配体范围宽的联芳基和联吡唑基膦。中性π-烯丙基铝络合物结合了一系列联芳基/联吡唑基膦配体，而阳离子支架则容纳了非常庞大的配体。这些络合物在温和条件下很容易被活化，并且对于一系列具有挑战性的C–C和C–X（X =杂原子）交叉偶联反应非常有效。它们的高活性与它们在常见的交叉偶联反应条件下易于活化为基于12电子的“ L-Pd（0）”催化剂，活化时释放非抑制性副产物以及抑制向形式双核（μ-烯丙基）（μ-Cl）Pd 2（L）2种，受结构（单晶X射线）和动力学研究的支持。低催化剂含量和短反应时间的广泛的C–C和C–X偶联反应突出了这些催化剂在有机合成中的多功能性和实用性。

  DOI：

  10.1021/acs.joc.5b01005

文献信息

• [EN] HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF<br/>[FR] INHIBITEURS DE LA VOIE SIGNALISATION HEDGEHOG ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：ZHANG XIAOHU

  公开号：WO2014113191A1

  公开（公告）日：2014-07-24

  The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders).

  刺猬（Hh）信号通路是一条在胚胎发育过程中调节图案形成、生长和细胞迁移的通路，但在成年后仅限于组织维护和修复。抑制性通路组分的突变失活导致刺猬信号通路的成熟配体无关激活，导致基底细胞癌和髓母细胞瘤等癌症的发生。刺猬信号的配体依赖性激活参与前列腺癌、胰腺癌、乳腺癌和血液癌的发生。因此，抑制异常的刺猬信号代表了一种有前途的新型抗癌疗法。该发明提供了一种抑制刺猬通路信号的化合物I的新分子，并为治疗恶性肿瘤（基底细胞癌、髓母细胞瘤、胶质母细胞瘤、非小细胞肺癌、前列腺癌、胰腺癌、血液癌、间叶细胞癌等）、预防肿瘤再生长、增强放疗和化疗的敏感性以及其他疾病（炎症、纤维化和免疫紊乱）的治疗应用。
• [EN] 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] DERIVES DE 3-AMINO-4-PHENYLBUTANOIQUE ACIDE UTILISES EN TANT QU'INHIBITEURS DE DIPEPTIDYL PEPTIDASE POUR LE TRAITEMENT OU LA PREVENTION DU DIABETE
  申请人：MERCK & CO INC

  公开号：WO2004058266A1

  公开（公告）日：2004-07-15

  The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及3-氨基-4-苯基丁酸衍生物，这些衍生物是二肽基肽酶-IV酶（'DP-IV抑制剂'）的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• Complexes
  申请人：JOHNSON MATTHEY PUBLIC LIMITED COMPANY

  公开号：US09777030B2

  公开（公告）日：2017-10-03

  A palladium(II) complex of formula (1) or a palladium(II) complex of formula (3). Also, processes for the preparation of the complexes, and their use in carbon-carbon and carbon-heteroatom coupling reactions.

  一种化学式为(1)的钯(II)配合物或化学式为(3)的钯(II)配合物。此外，还涉及制备这些配合物的方法，以及它们在碳-碳和碳-杂原子偶联反应中的用途。
• 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  申请人：Duffy L Joseph

  公开号：US20060052382A1

  公开（公告）日：2006-03-09

  The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及3-氨基-4-苯基丁酸衍生物，它们是二肽酶IV酶（“DP-IV抑制剂”）的抑制剂，对于涉及二肽酶IV酶的疾病，如糖尿病，特别是2型糖尿病的治疗或预防有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及二肽酶IV酶的这类疾病的预防或治疗中的使用。
• HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF
  申请人：Suzhou Yunxuan Yiyao Keji Youxian Gongsi

  公开号：US20160024095A1

  公开（公告）日：2016-01-28

  The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and some blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The present invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders) related to hedgehog signaling.

  刺猬（Hh）信号通路是一种在胚胎发育期间调节模式、生长和细胞迁移的通路，但在成年后仅限于组织维护和修复。抑制通路成分的突变失活导致Hh信号通路的构成性配体无关激活，导致基底细胞癌和髓母细胞瘤等癌症。Hh信号的配体依赖性激活涉及前列腺癌、胰腺癌、乳腺癌和一些血液癌症。因此，抑制异常的Hh信号是一种有前途的新型抗癌治疗方法。本发明提供了公式I的新型分子，可以抑制刺猬通路信号，并提供治疗恶性肿瘤（基底细胞癌、髓母细胞瘤、胶质母细胞瘤、非小细胞肺癌、前列腺癌、胰腺癌、血液癌症、间叶癌症等），预防肿瘤再生长，增强放化疗的敏感性，以及与刺猬信号相关的其他疾病（炎症、纤维化和免疫障碍）的治疗应用。